ADC Therapeutics (ADCT) News Today → Truth about Trump you’ve never heard (From Porter & Company) (Ad) Free ADCT Stock Alerts $3.99 -0.20 (-4.77%) (As of 05/14/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 15 at 7:15 AM | globenewswire.comADC Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQMay 10, 2024 | finance.yahoo.comADC Therapeutics First Quarter 2024 Earnings: In Line With ExpectationsMay 10, 2024 | insidertrades.comAmeet Mallik Sells 29,731 Shares of ADC Therapeutics SA (NYSE:ADCT) StockMay 9, 2024 | marketbeat.comInsider Selling: ADC Therapeutics SA (NYSE:ADCT) CEO Sells 29,731 Shares of StockADC Therapeutics SA (NYSE:ADCT - Get Free Report) CEO Ameet Mallik sold 29,731 shares of the stock in a transaction that occurred on Tuesday, May 7th. The stock was sold at an average price of $4.48, for a total transaction of $133,194.88. Following the completion of the sale, the chief executive officer now owns 1,167,348 shares of the company's stock, valued at approximately $5,229,719.04. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.May 9, 2024 | finance.yahoo.comInsider Sale: CEO Ameet Mallik Sells 29,731 Shares of ADC Therapeutics SA (ADCT)May 9, 2024 | finanznachrichten.deADC Therapeutics SA: ADC Therapeutics to Participate in 2024 RBC Capital Markets Global Healthcare ConferenceMay 9, 2024 | globenewswire.comADC Therapeutics to Participate in 2024 RBC Capital Markets Global Healthcare ConferenceMay 8, 2024 | americanbankingnews.comADC Therapeutics (NYSE:ADCT) Price Target Lowered to $8.00 at HC WainwrightMay 7, 2024 | markets.businessinsider.comBuy Rating Affirmed for ADC Therapeutics on Strong Zynlonta Clinical Data and Strategic Growth OutlookMay 7, 2024 | finance.yahoo.comADC Therapeutics SA (NYSE:ADCT) Q1 2024 Earnings Call TranscriptMay 7, 2024 | marketbeat.comHC Wainwright Cuts ADC Therapeutics (NYSE:ADCT) Price Target to $8.00HC Wainwright dropped their price target on ADC Therapeutics from $9.00 to $8.00 and set a "buy" rating for the company in a research report on Tuesday.May 7, 2024 | marketbeat.comADC Therapeutics (NYSE:ADCT) Announces Quarterly Earnings ResultsADC Therapeutics (NYSE:ADCT - Get Free Report) released its earnings results on Monday. The company reported ($0.56) EPS for the quarter, meeting the consensus estimate of ($0.56). ADC Therapeutics had a negative net margin of 344.15% and a negative return on equity of 1,313.37%. During the same quarter in the previous year, the company posted ($0.74) earnings per share.May 6, 2024 | finanznachrichten.deADC Therapeutics SA: ADC Therapeutics Announces $105 Million Underwritten Offering of Common Shares and Pre-Funded WarrantsMay 6, 2024 | finance.yahoo.comADC Therapeutics Announces $105 Million Underwritten Offering of Common Shares and Pre-Funded WarrantsMay 6, 2024 | investorplace.comADCT Stock Earnings: ADC Therapeutics Beats EPS, Misses Revenue for Q1 2024May 6, 2024 | globenewswire.comADC Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdatesMay 6, 2024 | globenewswire.comADC Therapeutics Announces Initial Data from Investigator-Initiated Phase 2 Clinical Trial of ZYNLONTA® in Patients with Relapsed/Refractory Marginal Zone LymphomaMay 2, 2024 | marketbeat.comADC Therapeutics (ADCT) Set to Announce Earnings on MondayADC Therapeutics (NYSE:ADCT) will be releasing earnings before the market opens on Monday, May 6, Zacks reports.May 1, 2024 | globenewswire.comADC Therapeutics Makes Grants to New Employees Under Inducement PlanMay 1, 2024 | finance.yahoo.comADC Therapeutics to Host First Quarter 2024 Financial Results and Pipeline Update Conference Call on May 6, 2024April 30, 2024 | seekingalpha.comADCT ADC Therapeutics SAApril 18, 2024 | marketbeat.comHC Wainwright Comments on ADC Therapeutics SA's Q1 2024 Earnings (NYSE:ADCT)ADC Therapeutics SA (NYSE:ADCT - Free Report) - Investment analysts at HC Wainwright cut their Q1 2024 earnings per share estimates for shares of ADC Therapeutics in a research note issued on Monday, April 15th. HC Wainwright analyst R. Burns now expects that the company will earn ($0.56) per shaApril 16, 2024 | marketbeat.comShort Interest in ADC Therapeutics SA (NYSE:ADCT) Rises By 5.7%ADC Therapeutics SA (NYSE:ADCT - Get Free Report) was the target of a large growth in short interest in the month of March. As of March 31st, there was short interest totalling 993,100 shares, a growth of 5.7% from the March 15th total of 939,800 shares. Based on an average daily trading volume, of 791,000 shares, the short-interest ratio is presently 1.3 days. Currently, 1.8% of the shares of the company are short sold.April 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for ADC Therapeutics on Strong Preclinical Data and Promising Trial ProgressApril 15, 2024 | marketbeat.comHC Wainwright Reiterates "Buy" Rating for ADC Therapeutics (NYSE:ADCT)HC Wainwright reissued a "buy" rating and set a $9.00 target price on shares of ADC Therapeutics in a report on Monday.April 5, 2024 | marketbeat.comADC Therapeutics' (ADCT) "Buy" Rating Reiterated at GuggenheimGuggenheim reissued a "buy" rating on shares of ADC Therapeutics in a research note on Friday.April 4, 2024 | msn.comADC Therapeutics gains after data for lymphoma therapyApril 4, 2024 | globenewswire.comADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin LymphomaApril 3, 2024 | globenewswire.comADC Therapeutics to Host a Virtual Research Investor Event on Tuesday, April 9, 2024April 1, 2024 | finance.yahoo.comADC Therapeutics Makes Grants to New Employees Under Inducement PlanMarch 28, 2024 | marketbeat.comADC Therapeutics SA (NYSE:ADCT) Receives Consensus Rating of "Hold" from BrokeragesShares of ADC Therapeutics SA (NYSE:ADCT - Get Free Report) have been assigned a consensus rating of "Hold" from the five research firms that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recomMarch 28, 2024 | marketbeat.comADC Therapeutics (NYSE:ADCT) Earns Buy Rating from Analysts at GuggenheimGuggenheim began coverage on shares of ADC Therapeutics in a research report on Thursday. They set a "buy" rating and a $11.00 price target on the stock.March 18, 2024 | marketbeat.comADC Therapeutics (NYSE:ADCT) Earns "Outperform" Rating from Royal Bank of CanadaRoyal Bank of Canada reaffirmed an "outperform" rating and issued a $8.00 price target on shares of ADC Therapeutics in a report on Thursday.March 16, 2024 | finance.yahoo.comUS$10.00 - That's What Analysts Think ADC Therapeutics SA (NYSE:ADCT) Is Worth After These ResultsMarch 15, 2024 | seekingalpha.comADC Therapeutics SA (ADCT) Q4 2023 Earnings Call TranscriptMarch 14, 2024 | finance.yahoo.comQ4 2023 ADC Therapeutics SA Earnings CallMarch 13, 2024 | finance.yahoo.comADC Therapeutics SA (ADCT) Reports Mixed 2023 Financial Results Amid Strategic ResetMarch 13, 2024 | marketbeat.comTrading was temporarily halted for "ADCT" at 09:03 AM with a stated reason of "LULD pause."March 13, 2024 | marketbeat.comTrading was temporarily halted for "ADCT" at 09:03 AM with a stated reason of "LULD pause."March 13, 2024 | marketbeat.comTrading was temporarily halted for "ADCT" at 09:03 AM with a stated reason of "LULD pause."March 13, 2024 | marketbeat.comTrading was temporarily halted for "ADCT" at 09:03 AM with a stated reason of "LULD pause."March 13, 2024 | globenewswire.comADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdatesMarch 6, 2024 | globenewswire.comADC Therapeutics to Participate in the Guggenheim 5th Annual Healthy Altitudes SummitMarch 6, 2024 | globenewswire.comADC Therapeutics to Host Fourth Quarter and Year-End 2023 Financial Results Conference Call on March 13, 2024March 5, 2024 | globenewswire.comADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research (AACR) Annual MeetingFebruary 27, 2024 | finanznachrichten.deADC Therapeutics SA: ADC Therapeutics to Participate in the TD Cowen 44th Annual Health Care ConferenceFebruary 27, 2024 | globenewswire.comADC Therapeutics to Participate in the TD Cowen 44th Annual Health Care ConferenceFebruary 25, 2024 | marketbeat.comADC Therapeutics (ADCT) Scheduled to Post Earnings on MondayADC Therapeutics (NYSE:ADCT) will be releasing earnings on Monday, February 26, Yahoo Finance reports.February 24, 2024 | msn.comADC Therapeutics (ADCT) Price Target Increased by 9.38% to 8.93February 23, 2024 | benzinga.comADC Therapeutics Stock (NYSE:ADCT), Quotes and News Summary Get ADC Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ADCT and its competitors with MarketBeat's FREE daily newsletter. Email Address Truth about Trump you’ve never heard (Ad)Everything about Donald Trump is public. Every part of his life has been dragged out in the media. But there’s one story I bet you’ve never heard about Trump. For the full story, click here. ADCT Media Mentions By Week ADCT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ADCT News Sentiment▼0.290.56▲Average Medical News Sentiment ADCT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ADCT Articles This Week▼82▲ADCT Articles Average Week Get ADC Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ADCT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: AMRN News ANRO News HROW News CRBP News ERAS News MREO News RANI News TERN News MRSN News ANNX News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:ADCT) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Monetary GoldForget the “Magnificent 7” Tech Companies, Buy This AI Stock InsteadBanyan Hill Publishingis this a buy and hold stock?Tips4TradersWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks NewsThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market InsidersBiden to Drop BOMBSHELL June 13th?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ADC Therapeutics SA Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
